skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Global director of content for Informa Pharma Intelligence, Mike Ward, talks to Kathy Harrison, CEO of Australian biotech Dimerix, about the company’s unusual business model. They discuss Dimerix’s Receptor-Heteromer Investigation Technology (HIT) platform and how it is used by the company and its partners. Dimerix’s pipeline is based on combining existing therapies with new drugs, a system it believes helps to lower risk to the company during the R&D phase. Dimerix’s lead compound is DMX-200, a Phase II chronic kidney disease treatment. DMX-200 is a combination of two existing drugs, irbesartan and propagermanium, which are already on the market in various regions around the world.

Read also


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: